Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
24.92
+0.14 (0.56%)
Sep 2, 2026, 11:45 AM EDT - Market open
Caris Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 989.61 | 812.03 | 412.26 | 306.13 | 258.49 | |
Revenue Growth | 85.37% | 96.97% | 34.67% | 18.43% | - |
Cost of Revenue | 298.37 | 271 | 231.83 | 214.87 | 178.46 |
Gross Profit | 691.23 | 541.04 | 180.43 | 91.26 | 80.02 |
Selling, General & Admin | 422.86 | 396.37 | 326.05 | 296.04 | 294.51 |
Research & Development | 115.12 | 99.56 | 111.5 | 114.77 | 101.27 |
Operating Expenses | 537.97 | 495.93 | 437.55 | 410.81 | 395.78 |
Operating Income | 153.26 | 45.11 | -257.12 | -319.55 | -315.76 |
Interest Expense | -46.9 | -56.85 | -50.03 | -31.61 | -26.68 |
Interest & Investment Income | 28.03 | 16.5 | 7.12 | 11.26 | 0.95 |
Other Non Operating Income (Expenses) | -2.17 | -52.95 | 18.14 | 9.4 | 20.66 |
EBT Excluding Unusual Items | 132.22 | -48.19 | -281.89 | -330.5 | -320.83 |
Other Unusual Items | -27.2 | -19.9 | - | -10.92 | - |
Pretax Income | 105.02 | -68.09 | -281.89 | -341.42 | -320.83 |
Net Income | 105.14 | -68.09 | -281.89 | -341.42 | -320.83 |
Preferred Dividends & Other Adjustments | - | 469.87 | 96.37 | 121.11 | 79 |
Net Income to Common | 105.14 | -537.96 | -378.26 | -462.53 | -399.83 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 283 | 167 | 35 | 35 | 33 |
Shares Outstanding (Diluted) | 283 | 167 | 35 | 35 | 33 |
Shares Change | 559.05% | 371.04% | 1.59% | 4.73% | - |
EPS (Basic) | 0.37 | -3.22 | -10.66 | -13.24 | -11.98 |
EPS (Diluted) | 0.37 | -3.22 | -10.66 | -13.24 | -11.98 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | 123.96 | 66.9 | -253.64 | -298.42 | -327.96 |
Free Cash Flow Per Share | 0.44 | 0.40 | -7.15 | -8.54 | -9.83 |
Gross Margin | 69.85% | 66.63% | 43.77% | 29.81% | 30.96% |
Operating Margin | 15.49% | 5.56% | -62.37% | -104.38% | -122.16% |
Profit Margin | 10.62% | -66.25% | -91.75% | -151.09% | -154.68% |
Free Cash Flow Margin | 12.53% | 8.24% | -61.52% | -97.48% | -126.88% |
EBITDA | 174.03 | 67.73 | -208.21 | -270.55 | -267.5 |
EBITDA Margin | 17.59% | 8.34% | -50.50% | -88.38% | -103.49% |
D&A For EBITDA | 20.76 | 22.62 | 48.91 | 49 | 48.25 |
EBIT | 153.26 | 45.11 | -257.12 | -319.55 | -315.76 |
EBIT Margin | 15.49% | 5.56% | -62.37% | -104.38% | -122.16% |
Revenue as Reported | 989.61 | 812.03 | 412.26 | 306.13 | 258.49 |
Advertising Expenses | - | 3.6 | 1.2 | 0.6 | 1 |